Skip to search formSkip to main contentSkip to account menu

elacytarabine

The lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As… 
National Institutes of Health

Related topics

Related topics

1 relation
CP-4055

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the…
Abstract Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of… 
2012
2012
A somatic EZH2 mutation in childhood acute myeloid leukemia
2012
2012
Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C
Abstract 3547 Objectives: Elacytarabine (CP-4055) is an elaidic acid ester of arabinosyl cytosine (Ara-C), administered as a… 
2012
2012
Mechanisms and consequences of the loss of PHLPP 1 phosphatase in chronic lymphocytic leukemia ( CLL )
elacytarabine CIV in the dose range 875 -2000 mg/m per day may allow more flexible administration and dosing than for ara-C. AUC… 
2012
2012
Elacytarabine — A New Agent in the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia
The prognosis for patients with relapsed acute myeloid leukaemia (AML) is poor, and effective treatments for this patient group… 
2011
2011
A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
TPS207 Background: Elacytarabine is a fatty acid derivative (elaidic acid ester) of the antimetabolite cytarabine,which is widely… 
Review
2011
Review
2011
A randomized phase III study of elacytarabine versus limited investigator's choice in patients with refractory acute myeloid leukemia (AML).
TPS206 Background: Elacytarabine is a novel chemical entity developed as an antineoplastic agent. It is a fatty acid derivative… 
2011
2011
A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the…
Abstract 1533 Background: Elacytarabine is a fatty acid derivative (elaidic acid ester) of cytarabine. The mechanism of action is… 
2010
2010
The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues
The clinical activity of pyrimidine analogues (araC and gemcitabine) is impaired by different mechanisms of resistance and… 
2010
2010
Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells
The deoxynucleoside analogs cytarabine (Ara-C) and gemcitabine (dFdC) are widely used in the treatment of cancer. Due to their… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)